Publications by authors named "Alexandria Dickson"

The recommended COVID-19 booster vaccine uptake is low. At-home lateral flow assay (LFA) antigen tests are widely accepted for detecting infection during the pandemic. Here, we present the feasibility and potential benefits of using LFA-based antibody tests as a means for individuals to detect inadequate immunity and make informed decisions about COVID-19 booster immunization.

View Article and Find Full Text PDF

Introduction: Vaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how the immune responses (antibodies and CD4 T cells) to SARS-CoV-2 from natural infection and vaccination change over time, focusing on variants like Mu, Gamma, and Delta.
  • It found that antibody levels decline after 6 months, particularly in mildly infected individuals, while those severely infected maintain higher levels; vaccination boosts antibody production but they also decrease over time.
  • The cross-recognition of variants showed varying effectiveness, and prior exposure to the virus influenced the immune response, suggesting important considerations for future vaccine development against emerging variants.
View Article and Find Full Text PDF

Unlabelled: Individuals with weaker neutralizing responses show reduced protection with SARS-CoV-2 variants. Booster vaccines are recommended for vaccinated individuals, but the uptake is low. We present the feasibility of utilizing point-of-care tests (POCT) to support evidence-based decision-making around COVID-19 booster vaccinations.

View Article and Find Full Text PDF
Article Synopsis
  • - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a respiratory disease with varying severity, and several risk factors for severe illness include age, male sex, and conditions like diabetes and obesity.
  • - Recent advancements in treatments such as corticosteroids have now become standard care for severe COVID-19 patients, but the molecular effects of these treatments on the immune response to the virus are still not fully understood.
  • - A study analyzed immune responses in hospitalized diabetic males with obesity, revealing that severe COVID-19 is linked to strong antibody responses and inflammation, whereas patients treated with steroids had reduced inflammation and indicators of cell death.
View Article and Find Full Text PDF

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry. The current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity.

View Article and Find Full Text PDF

The novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic. Critical to the rapid evaluation of vaccines and antivirals against SARS-CoV-2 is the development of tractable animal models to understand the adaptive immune response to the virus. To this end, the use of common laboratory strains of mice is hindered by significant divergence of the angiotensin-converting enzyme 2 (ACE2), which is the receptor required for entry of SARS-CoV-2.

View Article and Find Full Text PDF

The novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic resulting in nearly 20 million infections across the globe, as of August 2020. Critical to the rapid evaluation of vaccines and antivirals is the development of tractable animal models of infection. The use of common laboratory strains of mice to this end is hindered by significant divergence of the angiotensin-converting enzyme 2 (ACE2), which is the receptor required for entry of SARS-CoV-2.

View Article and Find Full Text PDF

In up to 15% of acute myeloid leukemias (AMLs), a recurring chromosomal translocation, termed t(8;21), generates the AML1-eight-twenty-one (ETO) leukemia fusion protein, which contains the DNA-binding domain of Runt-related transcription factor 1 (RUNX1) and almost all of ETO. RUNX1 and the AML1-ETO fusion protein are coexpressed in t(8;21) AML cells and antagonize each other's gene-regulatory functions. AML1-ETO represses transcription of RUNX1 target genes by competitively displacing RUNX1 and recruiting corepressors such as histone deacetylase 3 (HDAC3).

View Article and Find Full Text PDF